SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Economic Incentives for Evidence Generation: Promoting an Efficient Path to Personalized Medicine
10 references·1 citing·42 second hop
Economic Incentives for Evidence Generation: Promoting an Efficient Path to Personalized Medicine (2013)Economic Incentives for Evidence Generati…Encyclopedia of Health Economics (2014)Encyclopedia of Health Econom…Current Methodological Issues in the Economic Assessment of Personalized Medicine (2013)Current Methodological Issues…USING HEALTH TECHNOLOGY ASSESSMENT TO SUPPORT OPTIMAL USE OF TECHNOLOGIES IN CURRENT PRACTICE: THE CHALLENGE OF “DISINVESTMENT” (2012)USING HEALTH TECHNOLOGY ASSES…Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group (2012)Challenges in the Development…Market Access Challenges in the EU for High Medical Value Diagnostic Tests (2011)Market Access Challenges in t…Willingness‐to‐pay for predictive tests with no immediate treatment implications: a survey of US residents (2010)Willingness‐to‐pay for predic…Follow-on biologics: data exclusivity and the balance between innovation and competition (2008)Follow-on biologics: data exc…Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers (2007)Stratified medicine: strategi…Linking Pharmacogenetics-Based Diagnostics And Drugs For Personalized Medicine (2006)Linking Pharmacogenetics-Base…The Economics of Gene Therapy and of Pharmacogenetics (2002)The Economics of Gene Therapy…A Systematic Review of Health Economic Evaluations of Diagnostic Biomarkers (2015)A Systematic Review of Health…Returns on Research and Development for 1990s New Drug Introductions (2002)Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents (2003)The Economics of Follow-on Drug Research and Development (2004)R&D policy, agency costs and innovation in personalized medicine (2009)The price of innovation: new estimates of drug development costs (2003)Meta-analysis of individual participant data: rationale, conduct, and reporting (2010)Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? (2012)Biomarkers and clinical staging in psychiatry (2014)Risk, Ambiguity, and the Savage Axioms (1961)Statistical Efficiency of Double‐Bounded Dichotomous Choice Contingent Valuation (1991)Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)Assessing the Added Value of Health Technologies: Reconciling Different Perspectives (2012)Concepts of ‘Personalization’ in Personalized Medicine: Implications for Economic Evaluation (2014)Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis (2017)Cost-Effectiveness in Health and Medicine (1996)Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices—Modeling Studies (2003)Methods for the Economic Evaluation of Health Care Programmes (2005)The Future of Precision Medicine: Potential Impacts for Health Technology Assessment (2018)Cost-effectiveness of precision medicine: a scoping review (2019)Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group (2020)Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. (2005)Industrial Market Structure and Economic Performance. (1971)Protecting Their Intellectual Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (or Not) (2000)“New Drug” Designations for New Therapeutic Entities: New Active Substance, New Chemical Entity, New Biological Entity, New Molecular Entity (2014)Determinants of Market Exclusivity for Prescription Drugs in the United States (2017)The Impact of the Entry of Biosimilars: Evidence from Europe (2018)Guidelines for authors and peer reviewers of economic submissions to the BMJ (1996)National Institute for Clinical Excellence and its value judgments (2004)Valuing the ICECAP capability index for older people (2008)Economic evaluations of personalized medicine: existing challenges and current developments (2015)Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough Solutions (2018)The economic case for precision medicine (2018)Prospect theory: An analysis of decision under risk (1988)Prospect Theory: An Analysis of Decision under Risk (2000)BEST PRACTICE IN UNDERTAKING AND REPORTING HEALTH TECHNOLOGY ASSESSMENTS (2002)How OECD health systems define the range of good and services to be financed collectively (2016)HTA Implementation Roadmap in Central and Eastern European Countries (2016)GRADE EVIDENCE TO DECISION (EtD) FRAMEWORK FOR COVERAGE DECISIONS (2017)Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics (2017)Comparing and Explaining Differences in the Magnitude, Content, and Sensitivity of Utilities Predicted by the EQ-5D, SF-6D, HUI 3, 15D, QWB, and AQoL-8D Multiattribute Utility Instruments (2014)Patient and general public preferences for health states: A call to reconsider current guidelines (2016)Socio‐Economic Inequalities in Health Care in England (2016)
this work references cited by second hop

References

  • 2007Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers510 cited
  • 2014Encyclopedia of Health Economics217 cited
  • 2012Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group161 cited
  • 2010Willingness‐to‐pay for predictive tests with no immediate treatment implications: a survey of US residents141 cited
  • 2013Current Methodological Issues in the Economic Assessment of Personalized Medicine93 cited
  • 2002The Economics of Gene Therapy and of Pharmacogenetics90 cited
  • 2008Follow-on biologics: data exclusivity and the balance between innovation and competition89 cited
  • 2012USING HEALTH TECHNOLOGY ASSESSMENT TO SUPPORT OPTIMAL USE OF TECHNOLOGIES IN CURRENT PRACTICE: THE CHALLENGE OF “DISINVESTMENT”82 cited
  • 2011Market Access Challenges in the EU for High Medical Value Diagnostic Tests63 cited
  • 2006Linking Pharmacogenetics-Based Diagnostics And Drugs For Personalized Medicine61 cited

Cited by

  • 2015A Systematic Review of Health Economic Evaluations of Diagnostic Biomarkers53 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work